-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Best Practices for Peer Review: ASH Clinical News interviews the Blood Advances Editors (for in-person participants)

Program: Blood Journals Studio
Monday, December 11, 2023: 11:00 AM-12:00 PM
Halls G-H - Blood Journals Studio (San Diego Convention Center)
Catherine M. Bollard, MD, Children's National Hospital and The George Washington University and Aaron T. Gerds, MD, MS, Cleveland Clinic
Bollard: Cabaletta Bio, Catamaran Bio: Current equity holder in private company, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties: Patent applications in CAR-NKs; Roche: Consultancy. Gerds: AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, GlaxoSmithKline, Kartos, Novartis, PharmaEssentia, Sierra Oncology: Consultancy; Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation, Kratos Pharmaceuticals: Research Funding.
Dr. Aaron Gerds, Editor-in-Chief of ASH Clinical News, interviews Blood Advances Editor-in-Chief Dr. Catherine Bollard and Deputy Editor Andrew Weyrich on the topic of peer review.
See more of: Blood Journals Studio